Malignancy - Medicow
About us  |  Why use us?  |  Press  |  Contact us

 

Topic: Malignancy



  
 Cancer - Wikipedia, the free encyclopedia
Biopsy and microscopical examination can also distinguish between malignancy and hyperplasia, which refers to tissue growth based on an excessive rate of cell division, leading to a larger than usual number of cells but with a normal orderly arrangement of cells within the tissue.
Hematological malignancies, such as leukemia and lymphoma, arise from blood and bone marrow.
Prolonged exposure to radiation, particularly ultraviolet radiation from the sun, leads to melanoma and other skin malignancies.
http://en.wikipedia.org/wiki/Cancer   (5818 words)

  
 Stanford Cancer Center - Leukemia & Hematological Malignancies
Leukemia is cancer of the blood and develops in the bone marrow.
Patients with leukemia are evaluated and treated in Stanford's Hematology and Bone Marrow Transplant clinics by a team of world-renowned physicians.
Our goal is to improve the survival and quality of life of patients.
http://cancer.stanfordhospital.com/cancerTypes/leukemias   (799 words)

  
 Clinically Useful Information Provided by the Flow Cytometric Immunophenotyping of Hematological Malignancies: Current Status and Future Directions -- Orfao et al. 45 (10): 1708 -- Clinical Chemistry
Recent advances in flow cytometry: applications to the diagnosis of hematologic malignancy.
Leukaemias with megakaryoblastic involvement: clinical, hematological and immunological characteristics.
U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation.
http://www.clinchem.org/cgi/content/full/45/10/1708   (6845 words)

  
 Hematological Malignancies, University of Minnesota Cancer Center
The hematological malignancy multidisciplinary program is actively engaged in both national and regional clinical trials for hematological malignant tumors.
If you take part in a clinical trial, you may benefit from a new drug, procedure, or symptom-control method while helping scientists evaluate its effectiveness.
You may search the Cancer Center's clinical trial database to find a current list of trials for lymphoma, myeloma, and leukemia, or contact our program coordinators.
http://www.cancer.umn.edu/page/clinical/hemato.html   (1990 words)

  
 Molecular genetic biomarkers in hematological malignancies.
These concepts may provide the stage for the creation of chemoprevention studies in leukemia and lymphoma.
This makes them less amenable to conventional early screening methods such as imaging and observation.
Most hematopoietic malignancies are widely disseminated even in their "early" stages and often do not have a well-defined localized phase.
http://www.aegis.com/aidsline/1997/jun/M9760506.html   (392 words)

  
 Title page for etd-0909104-145326
Conclusion: although our study is a primary result, study cases are varied, but it still provide important information that VEGF has an important role in hematological malignancies.
We will process further research of single and specific disease in the future to analyze the exact correlation of VEGF and hematological diseases.
This study will examine the VEGF secretary activity of malignant cells in the patients with hematologic malignancies.
http://etd.lib.nsysu.edu.tw/ETD-db/ETD-search/view_etd?URN=etd-0909104-145326   (407 words)

  
 Hematological malignancy - Wikipedia, the free encyclopedia
In general, a bone marrow biopsy is part of the "work up" for the analysis of these diseases.
This leads to a different approach in diagnosis and treatment of hematological malignancies.
Hematological malignancies are the types of cancer that affect blood, bone marrow and lymph nodes.
http://en.wikipedia.org/wiki/Hematological_malignancy   (404 words)

  
 Radiological Imaging in Hematological Malignancies - Compare Shop Books
The third part documents the effects of therapy on each anatomical group of organs in patients treated in Hematology.
25 Musculoskeletal Effects of Therapy in Patients Treated for Hematological Malignancies 485
23 The Treated Thorax in Patients with Hematological Malignancies 443
http://www.compareshopbooks.com/3540439994.htm   (272 words)

  
 Phase I Study of Oral Topotecan in Hematological Malignancies -- Beran et al. 9 (11): 4084 -- Clinical Cancer Research
response, and six (25%) patients experienced hematological improvement.
(MTD) of oral topotecan in patients with hematological malignancies.
The MTD for oral topotecan in patients with hematological
http://clincancerres.aacrjournals.org/cgi/content/abstract/9/11/4084   (355 words)

  
 Aspergillus/Aspergillosis website
This assay has been evaluated with serum mainly from patients receiving treatment for hematological malignancies and although the specificity of the LA-test was high, substantial variation in sensitivity was observed (Table 1) (1,6-12).
Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies.
37 pediatric patients with hematological malignancies, including 15 BMT recipients
http://www.aspergillus.man.ac.uk/secure/diagnosis/verweij.html   (1870 words)

  
 Biochemical and Genetic Control of Apoptosis: Relevance to Normal Hematopoiesis and Hematological Malignancies -- Wickremasinghe and Hoffbrand 93 (11): 3587 -- Blood
Ataxia telangiectasia patients show a high incidence of lymphoid, but not of myeloid, malignancies.
the treatment of hematopoietic malignancies that are resistant
The expression of BCL-2 by the malignant cells of ALL patients at presentation is highly variable.
http://www.bloodjournal.org/cgi/content/full/93/11/3587   (6618 words)

  
 UPCI 02-03 sci. rpt. hematological malignancies overview
The program intends their work to ultimately produce innovative and effective treatment methods for combating blood cancers.
Accordingly, much of the program's research is focused on the genetic and cellular origins of leukemia, lymphoma and myeloproliferative disorders, as well as the development of agents used in treating hematologic malignancies.
The Hematological Malignancies Program of the University of Pittsburgh Cancer Institute investigates the mechanisms involved with the onset and progress of blood disorders, and also studies novel methods by which these processes can be altered.
http://www.upci.upmc.edu/report/Clinical/hema   (143 words)

  
 Dendritic Cell-Based Vaccines in Patients with Hematological Malignancies -- BRUGGER et al. 938 (1): 359 -- Annals of the New York Academy of Sciences
Dendritic Cell-Based Vaccines in Patients with Hematological Malignancies
Dendritic Cell-Based Vaccines in Patients with Hematological Malignancies -- BRUGGER et al.
malignancies as well as on some B-cell lymphomas and multiple
http://www.annalsnyas.org/cgi/content/abstract/938/1/359   (217 words)

  
 ICML: Campath-1H and Rituximab for the Treatment of Hematological Malignancies
ICML: Campath-1H and Rituximab for the Treatment of Hematological Malignancies
Title: ICML: Campath-1H and Rituximab for the Treatment of Hematological Malignancies
LUGANO, SWITZERLAND -- June 16, 2002 -- The combination of the monoclonal antibodies campath-1H and rituximab is safe and effective in patients with relapsed and/or refractory hematological malignancies, according to the results of an exploratory study.
http://www.docguide.com/dg.nsf/PrintPrint/639CF59AC6B000E785256BDA00606D78   (550 words)

  
 brain breast cancer tumor
Complex Medicine, a System of Healing Heart, Brain and Body,
Search News and Events Cancer News Archive Search the Archive Keyword all cancers anal cancer bladder cancer brain cancer/tumor breast cancer cervical cancer childhood cancers colon / rectal cancers...
Examples include: bladder carcinoma, blood (and bone marrow)- hematological malignancies, leukemia, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, brain tumor, breast cancer...
http://brain-cancer.info/brainbreastcancertumor   (1108 words)

  
 Encyclopedia: Anemia
Although hematological malignancies are a form of cancer, they are generally treated by specialists in hematology, although in many hospitals oncology specialists also manage these diseases.
Leukemia (leukaemia in Commonwealth English) is a group of blood diseases characterized by malignancies (cancer) of the blood-forming tissues.
Hypogonadism is a medical term for a defect of the reproductive system which results in lack of function of the gonads (ovaries or testes).
http://www.nationmaster.com/encyclopedia/Anemia   (4460 words)

  
 A NOVEL VACCINE FOR HEMATOLOGICAL MALIGNANCIES USING DENDRITIC CELLS
Such specific anti-leukemic donor CTLs may be utilized to maximize the anti-tumor effects of DLI in patients relapsing after allogeneic transplantation.
Allogeneic stem cell transplantation has a significant contribution to the improved outcome of patients with hematological malignancies.
Nevertheless, a significant proportion of patients suffer from recurrence of the disease, which ultimately leads to death.
http://www.celltherapy.org/Abstracts2004/Abstracts/080.htm   (244 words)

  
 Multiple Myeloma Treatment - Multiple Myeloma symptoms.
Introduction: the evolving role of bisphosphonate therapy in multiple myeloma.
Questions to ask your doctor, new developments and breakthrough treatments.
The immune system is composed of several types of cells that work together to fight off infection and other disease.
http://clikngo.com/medical/HM008.HTM   (684 words)

  
 Genes at Work - Lab Testing
In some chronic hematologic disorders, longer incubation or short term stimulation with PHA or other mitogen may be required.
In the clinical setting, cytogenetic analysis has proven to be an invaluable tool in the diagnosis, prognosis, and management of hematologic malignancies.
Chromosomal abnormalities in hematological malignancies are strongly correlated with tumor type and may play a role in earliest stages of tumor initiation.
http://www.umdnj.edu/genesatwork/labtesting/27_nonrandom.html   (568 words)

  
 Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment -- Dimeo et al. 15 (8): 1237 -- Annals of Oncology
Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment
Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment -- Dimeo et al.
Background: Fatigue is a frequent and severe problem after treatment
http://annonc.oxfordjournals.org/cgi/content/abstract/15/8/1237   (272 words)

  
 The Epithelial Tumor Antigen MUC1 Is Expressed in Hematological Malignancies and Is Recognized by MUC1-specific Cytotoxic T-Lymphocytes -- Brossart et al. 61 (18): 6846 -- Cancer Research
Copyright © 2001 by the American Association for Cancer Research.
The Epithelial Tumor Antigen MUC1 Is Expressed in Hematological Malignancies and Is Recognized by MUC1-specific Cytotoxic T-Lymphocytes
The Epithelial Tumor Antigen MUC1 Is Expressed in Hematological Malignancies and Is Recognized by MUC1-specific Cytotoxic T-Lymphocytes -- Brossart et al.
http://cancerres.aacrjournals.org/cgi/content/abstract/61/18/6846   (843 words)

  
 Cancer Cell Biology
Haier, J. and Nicolson, G.L. Hematological malignancies in cancer research.
Researchers at the Institute for Molecular Medicine have found that multiple adhesive mechanisms are responsible for malignant cell adhesion to microvessel endothelial cells and to underlying subendothelial matrix, and they have begun to identify and isolate the receptors responsible.
Nicolson, G.L. and Nasralla, M. Advantages and limitations of models for cancer and malignant cell progression in breast cancer.
http://www.immed.org/illness/cancer_cell_biology_research.html   (4324 words)

  
 Listeriosis in hematological malignancies: report of two cases.
Listeriosis occurred in two patients with hematological malignancies, one with adult T-cell leukemia (ATL) (Case 1) and the other with chronic granulocytic leukemia (CGL) (Case 2).
The state of the art may have changed since the publication date.
In Case 1, listeriosis was the initial manifestation of ATL, while it occurred in Case 2 after prolonged treatment with an alkylating agent and splenic irradiation.
http://www.aegis.com/aidsline/1989/sep/M8990458.html   (349 words)

  
 FASEB 2001 Conference on Hematological Malignancies
New techniques to classify these types of cancers are badly needed, since, often, it is difficult to predict how patients will progress and which patients will respond to certain therapies.
Thus, PML sumolation promotes its own catabolism, suggesting that mature nuclear bodies could be sites of intranuclear proteolysis.

T and B Leukemias: Mouse Models

New animal models are greatly needed to study hematological malignancies, as they provide insight about disease pathogenesis and allow for testing of new therapeutics.
Resulting fluorescent intensities are collected using a laser confocal fluorescent microscope, and ratio information is used to compare expression levels for each gene between the 2 cell types.

This "expression profiling" is valuable for leukemia researchers, who hope to classify and subclassify the different hematological malignancies based on molecular data, rather than clinical information only.

http://www.medscape.com/content/2001/00/40/84/408469/408469.xml   (3180 words)

  
 Expression in Hematological Malignancies of a Glucocorticoid Receptor Splice Variant That Augments Glucocorticoid Receptor-mediated Effects in Transfected Cells -- de Lange et al. 61 (10): 3937 -- Cancer Research
The effects of glucocorticoids are mediated through the glucocorticoid
Glucocorticoids play an important role in the treatment of a
malignancies and may be involved in the GC response of tumors
http://cancerres.aacrjournals.org/cgi/content/full/61/10/3937   (4122 words)

  
 Clinical Trial: STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients with Hematologic Malignancies
Male and female patient 18 years and older with histologically or cytologically confirmed hematological malignancy [other than acute myeloid leukemia (AML)and myelodysplastic syndrome (MDS)] and if treatment is medically indicated
The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies.
STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients with Hematologic Malignancies
http://clinicaltrials.gov/ct/show/NCT00088101?order=1   (542 words)

  
 Hematological Malignancies - Support & Understanding
When you or a loved one first hear the diagnosis of a hematological malignancy (blood cancer) such as leukemia or lymphoma, you may understandably feel anxious and unsure about the future.
However, many people find that learning about their condition can actually help relieve their fears and allow them to focus on maintaining their quality of life.
If you cannot find the information you need, you may wish to use our search facility
http://www.hemonc-usa.com   (239 words)

  
 Mismatch repair deficiency in hematological malignancies with microsatellite instability
MSI has also been observed in hematological malignancies, but whether these hematological malignancies are associated with MMR deficiency is still unclear.
Using both biochemical and genetic approaches, this study analysed MMR proficiency in 11 cell lines derived from patients with hematological malignancies and demonstrated that six out of seven hematological cancer cell lines with MSI were defective in strand-specific MMR.
From these results, we conclude that, as in solid tumors, hematological malignancies with MSI are also associated with MMR deficiency, and that the cause of MMR deficiency in these cell lines is due to a defective MutS
http://www.nature.com/doifinder/10.1038/sj.onc.1205695   (326 words)

  
 Cellular immunotherapy of hematological malignancies
Hematologie > Research > Cellular immunotherapy of hematological malignancies
http://www.lumc.nl/4010/research/Cellular_immunotherapy.html   (174 words)

  
 PXD101 for Solid and Hematological Malignancies in Phase I
PXD101 for Solid and Hematological Malignancies in Phase I
PXD101 appears to selectively target cancer cells and will be investigated for both solid and hematological malignancies
http://www.curagen.com/presentation/pxd101/tsld004.htm   (51 words)

 About us   |  Why use us?   |  Press   |  Contact us

 Copyright © 2006 Medicow.com Usage implies agreement with terms.